POA

POA Pharma is a specialty pharmaceutical company headquartered in Sweden that focuses on the development and commercialization of products for rare diseases and metabolic disorders. The company is particularly well-known for its extensive portfolio of medical foods and nutritional supplements designed for patients with inborn errors of metabolism, such as Phenylketonuria (PKU). In addition to its metabolic focus, POA Pharma markets a range of specialty medicines across Northern Europe and North America, covering therapeutic areas like endocrinology and emergency medicine. Since its acquisition by the Galenica Group, the company has expanded its reach as a boutique distributor and developer of niche healthcare solutions.